Insider Selling: Phibro Animal Health (NASDAQ:PAHC) CEO Sells $304,456.32 in Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 7,551 shares of the company’s stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $40.32, for a total transaction of $304,456.32. Following the sale, the chief executive officer directly owned 31,108 shares of the company’s stock, valued at $1,254,274.56. The trade was a 19.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Jack Bendheim also recently made the following trade(s):

• On Thursday, January 15th, Jack Bendheim sold 2,932 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.02, for a total transaction of $117,338.64.
• On Wednesday, January 14th, Jack Bendheim sold 3,651 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.53, for a total transaction of $147,975.03.
• On Friday, January 9th, Jack Bendheim sold 213 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.16, for a total transaction of $8,554.08.
• On Wednesday, January 7th, Jack Bendheim sold 328 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.09, for a total transaction of $13,149.52.
• On Thursday, December 11th, Jack Bendheim sold 5,752 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.93, for a total transaction of $235,429.36.
• On Tuesday, December 9th, Jack Bendheim sold 1,288 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.19, for a total value of $51,764.72.
• On Monday, December 8th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.06, for a total value of $141,011.20.
• On Wednesday, December 3rd, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.77, for a total value of $143,510.40.
• On Tuesday, November 25th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $43.93, for a total value of $309,267.20.
• On Wednesday, November 26th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The stock was sold at an average price of $44.02, for a total value of $232,425.60.

Phibro Animal Health Stock Up 2.5%

PAHC stock opened at $41.07 on Friday. The business’s 50-day moving average price is $40.59 and its 200-day moving average price is $37.10. The stock has a market cap of $1.66 billion, a P/E ratio of 24.74, a PEG ratio of 1.16 and a beta of 0.79. The company has a quick ratio of 1.35, a current ratio of 3.09 and a debt-to-equity ratio of 2.32. Phibro Animal Health Corporation has a twelve month low of $16.16 and a twelve month high of $46.42.

Phibro Animal Health (NASDAQ:PAHC) last released its earnings results on Wednesday, November 5th. The company reported $0.73 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.15. The company had revenue of $363.89 million for the quarter, compared to analysts’ expectations of $345.44 million. Phibro Animal Health had a net margin of 4.85% and a return on equity of 36.26%. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. On average, equities research analysts forecast that Phibro Animal Health Corporation will post 1.95 EPS for the current year.

Phibro Animal Health Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, December 17th. Investors of record on Wednesday, November 26th were issued a $0.12 dividend. The ex-dividend date of this dividend was Wednesday, November 26th. This represents a $0.48 annualized dividend and a yield of 1.2%. Phibro Animal Health’s dividend payout ratio is currently 28.92%.

Hedge Funds Weigh In On Phibro Animal Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Financial Management Professionals Inc. bought a new stake in Phibro Animal Health in the 2nd quarter worth approximately $32,000. Hughes Financial Services LLC purchased a new position in shares of Phibro Animal Health in the third quarter valued at $40,000. iSAM Funds UK Ltd bought a new stake in Phibro Animal Health in the third quarter worth $61,000. EverSource Wealth Advisors LLC raised its stake in Phibro Animal Health by 7,671.4% during the second quarter. EverSource Wealth Advisors LLC now owns 2,720 shares of the company’s stock valued at $69,000 after purchasing an additional 2,685 shares in the last quarter. Finally, Advisory Services Network LLC purchased a new stake in Phibro Animal Health during the third quarter valued at $96,000. 99.34% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

PAHC has been the topic of several research analyst reports. Zacks Research upgraded Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 9th. Weiss Ratings reissued a “buy (b-)” rating on shares of Phibro Animal Health in a research note on Monday, December 29th. Finally, JPMorgan Chase & Co. upped their price target on Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Phibro Animal Health presently has an average rating of “Hold” and an average price target of $31.40.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.